A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

NCT00724919

Last updated date
Study Location
Miaoli County, , 351, Taiwan
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

InfectionVoriconazole as Prophylactic Therapy in Lung Transplant Recipients
NCT00455364
  1. Chicago, Illinois
ALL GENDERS
18 Years+
years
MULTIPLE SITES
InfectionMDR Bacilli Surveillance and Clinical Feature in China
NCT02140853
  1. Guangzhou, Guangdong
ALL GENDERS
18 Years+
years
MULTIPLE SITES
InfectionA Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
NCT00724919
  1. Miaoli County,
  2. Taichung,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
Official Title Association of Antibiotic Utilization Measures and Control of Extended-Spectrum ?-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)
Brief Summary To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres
Detailed Description This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population patients admitted to ICU/burn unit
Condition Infection
Intervention Not Provided
Study Groups/Cohorts 1
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 25, 2008)
256
Original Actual Enrollment Same as current
Actual Study Completion Date April 2004
Actual Primary Completion Date April 2004   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion

  1. All patients admitted or transferred to ICU/burn unit.
  2. Patients of either sex, 18 years of age or older. Exclusion

Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number NCT00724919
Other Study ID Numbers 0910X-101440
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date August 2008